Products of advanced glycation in patients with type 2 diabetes and vascular disease

Annals of Clinical Biochemistry

Volumn 40, Issue 5, 2003, Pages 552-559

  Turk, Zdenka ^a,c   Sesto M ^b   Skodlar, J ^b   Ferencak G ^c   Pokupec, R ^d   Turk, N ^d   Stavljenic Rukavina A ^c  

^a University of Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c KBC Zagreb   (Croatia)

^d UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; EPITOPE;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCATION; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; VASCULAR DISEASE;

ADULT; AGED; BLOOD GLUCOSE; CORONARY ARTERIOSCLEROSIS; CREATININE; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED;

EID: 0141741163     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/000456303322326489     Document Type: Article

References (22)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
2. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12
3. Vlassara H, Bucala R, Striker L. Pathogenic effects of AGEs: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 70: 138-51
4. Njoroge FG, Monnier VM. The chemistry of the Maillard reaction under physiological conditions: a review. In: Baynes JW, Monnier VM, eds. The Maillard Reaction and Aging, Diabetes and Nutrition. New York: AR Liss, 1989: 85-109
5. Thornalley PJ. The clinical significance of glycation. Clin Lab 1999; 45: 263-73.
6. Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF. Serum concentrations of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 1999; 22: 1543-8
7. Turk Z, Mesić R, Benko B. Comparison of advanced glycation endproducts on haemoglobin (Hb-AGE) and haemoglobin A1c for the assessment of diabetic control. Clin Chim Acta 1998; 277: 159-70
8. Berg TJ, Bangstad HJ, Torjesen PA, Osterby R, Bucala R, Hanssen KF. Advanced giycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 1997; 46: 661-5
9. Mišur I, Turk Z, Barada A, Miličević Z, Metelko Ž. Advanced glycation endproducts in human diabetic peripheral nerve. Diabetologia 2001; 44 (Suppl 1): A318
10. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, et al. Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993; 143: 1649-56
11. Horiuchi S, Araki N, Morino Y. Immunochemical approach to characterize advanced glycation endproducts of the Maillard reaction. J Biol Chem 1991; 266: 7329-32
12. Baydanoff S, Konova E, Ivanova N. Determination of anti-AGE antibodies in human serum. Glycoconj J 1996; 13: 335-9
13. Turk Z, Ljubić S, Benko B, Granić M. Antibodies in NIDDM serum binding to advanced glycation modified proteins. Diabetologia 1999; 42 (Suppl 1): 57A
14. ε-(carboxymethyl)lysine. An advanced glycation end product of the Maillard reaction. Diabetes 1999; 48: 1842-9
15. Turk Z, Ljubic S, Turk N, Benko B. Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus. Clin Chim Acta 2001; 303: 105-15
16. ε -(carboxymethyl)lysine in healthy controls and diabetic patients. Diabetologia 2000; 43: 1385-8
17. Festa A, Kopp HP, Schernthaner G, Menzel EJ. Autoantibodies to oxidized low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications. Diabetologia 1998; 41: 350-6
18. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by amplification and cleavage with Hha I. J Lipid Res 1990; 31: 545-8
19. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, et al. Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure. Lancet 1994; 343: 1519-22
20. Miyata T, Ueda T, Shinzato T, Iida Y, Tanaka S, Kurakawa K, et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996; 7: 1198-206
21. Weiss MF. Pathogenic role of advanced glycation end-products: an overview. Perit Dial Int 1999; 19 (Suppl 2): S47-52
22. Kanauchi M, Tsujimoto N, Hashimoto T. Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care 2001; 24: 1620-3